A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients

Inclusion Criteria

• •Men and women with idiopathic Parkinson's disease
• •Subjects must experience motor fluctuations associated with LD/CD dosing
• •Modified Hoehn and Yahr stage \< 5
• •Subjects must be taking optimized and stable levodopa/dopa decarboxylase inhibitor therapy
• •Women must be postmenopausal, surgically sterilized, or using adequate birth control. Women of childbearing potential must have a negative pregnancy test (serum beta-HCG) at screening.
• •Subjects must be age 30 or older.
• •Subjects must be willing and able to give informed consent.